50358-42-4 Usage
Uses
Used in Pharmaceutical Industry:
6-Quinolinamine,5-bromo-(9CI) is used as an intermediate compound for the synthesis of various pharmaceuticals and drug candidates. Its unique structure and reactivity allow for the development of new drugs with potential applications in treating different diseases.
Used in Chemical Synthesis:
6-Quinolinamine,5-bromo-(9CI) is used as a building block in the synthesis of complex organic molecules and compounds. Its electrophilic and nucleophilic substitution reactions enable the creation of a diverse range of chemical products, including those with potential applications in materials science, agrochemicals, and other industries.
Used in Medicinal Chemistry:
6-Quinolinamine,5-bromo-(9CI) is used as a key component in the design and development of novel therapeutic agents. Its biological and pharmacological activities make it a promising candidate for the treatment of various medical conditions, including cancer, inflammation, and infectious diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 50358-42-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,3,5 and 8 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 50358-42:
(7*5)+(6*0)+(5*3)+(4*5)+(3*8)+(2*4)+(1*2)=104
104 % 10 = 4
So 50358-42-4 is a valid CAS Registry Number.
50358-42-4Relevant academic research and scientific papers
DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS
-
Page/Page column 28, (2010/07/04)
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5 and Ra are as defined herein. Also disclosed are methods of making the compounds a
QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS
-
Page/Page column 26, (2010/11/08)
The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
